Skip to main content
Submitted by osutra_adm1n on 13, Dec 2020

Rohan et al at the Medical University of South Carolina in Charleston, SC, recently evaluated the first 22 renal transplant recipients to receive clinical immune monitoring with donor-reactive T-cytotoxic memory cells. This cell type determines the likelihood of rejection in the Pleximark test. Increased donor-reactivity was associated with renal allograft rejection with a sensitivity of 83% and a negative predictive value of 91%. This increased reactivity also correlated with (r=0.453, p=0.03) with graft dysfunction measured with serum creatinine…....

Reference: Rohan VS, Soliman KM, Alqassieh A, Alkhader D, Pate N, Nadig SN. Renal allograft surveillance with allospecific T-cytotoxic memory cells. Ren Fail. 2020 Nov;42(1):1152-1156. doi: 10.1080/0886022X.2020.1846054. PMID: 33203287.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact